eTable 1. Age-Adjusted Characteristics Compared (Mean ± SE or N [%]) Between Women With and Without Missing Data on 25-Hydroxyvitamin D (25[OH]D) Concentrations and Genetics: The CAREDS
eTable 2. Distribution of AMD Cases by Severity: The CAREDS
eTable 3. Association Between SNPs in Genes Involved in Vitamin D Metabolism, Transport, and Genomic Function and Age-Related Macular Degeneration in a Subset of CAREDS Participants <75 Years of Age With Genetic Data (n=1230)
Customize your JAMA Network experience by selecting one or more topics from the list below.
Millen AE, Meyers KJ, Liu Z, et al. Association Between Vitamin D Status and Age-Related Macular Degeneration by Genetic Risk. JAMA Ophthalmol. 2015;133(10):1171–1179. doi:10.1001/jamaophthalmol.2015.2715
Deficient 25-hydroxyvitamin D (25[OH]D) concentrations have been associated with increased odds of age-related macular degeneration (AMD).
To examine whether this association is modified by genetic risk for AMD and whether there is an association between AMD and single-nucleotide polymorphisms of genes involved in vitamin D transport, metabolism, and genomic function.
Design, Setting, and Participants
Postmenopausal women (N = 913) who were participants of the Carotenoids in Age-Related Eye Disease Study (CAREDS) (aged 54 to <75 years) with available serum 25(OH)D concentrations (assessed October 1, 1993, to December 31, 1998), genetic data, and measures of AMD (n = 142) assessed at CAREDS baseline from May 14, 2001, through January 31, 2004, were studied.
Main Outcomes and Measures
Prevalent early or late AMD was determined from graded, stereoscopic fundus photographs. Logistic regression was used to estimate odds ratios (ORs) and 95% CIs for AMD by the joint effects of 25(OH)D (<12, ≥12 to <20, ≥20 to <30, and ≥30 ng/mL) and risk genotype (noncarrier, 1 risk allele, or 2 risk alleles). The referent group was noncarriers with adequate vitamin D status (≥30 ng/mL). Joint effect ORs were adjusted for age, smoking, iris pigmentation, self-reported cardiovascular disease, self-reported diabetes status, and hormone use. Additive and multiplicative interactions were assessed using the synergy index (SI) and an interaction term, respectively. To examine the association between AMD and variants in vitamin D–related genes, age-adjusted ORs and 95% CIs were estimated using logistic regression.
Among the 913 women, 550 had adequate levels of vitamin D (≥20 ng/mL), 275 had inadequate levels (≥12 to <20 mg/mL), and 88 had deficient levels (<12 ng/mL). A 6.7-fold increased odds of AMD (95% CI, 1.6-28.2) was observed among women with deficient vitamin D status (25[OH]D <12 ng/mL) and 2 risk alleles for CFH Y402H (SI for additive interaction, 1.4; 95% CI, 1.1-1.7; P for multiplicative interaction = .25). Significant additive (SI, 1.4; 95% CI, 1.1-1.7) and multiplicative interactions (P = .02) were observed for deficient women with 2 high-risk CFI (rs10033900) alleles (OR, 6.3; 95% CI, 1.6-24.2). The odds of AMD did not differ by genotype of candidate vitamin D genes.
Conclusions and Relevance
In this study, the odds of AMD were highest in those with deficient vitamin D status and 2 risk alleles for the CFH and CFI genotypes, suggesting a synergistic effect between vitamin D status and complement cascade protein function. Limited sample size led to wide CIs. Findings may be due to chance or explained by residual confounding.
Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in older Americans,1 has no cure, and has only limited treatment options. Research indicates a role for inflammation in the pathogenesis of AMD.2 Individuals with a history of inflammatory diseases have been found to have an increased risk of AMD,3,4 and markers of systemic inflammation have been positively associated with late AMD.5 Inflammatory molecules are found within drusen, suggesting that these accumulations elicit a local chronic inflammation.6 In addition, variants in genes for inflammatory response proteins are associated with AMD risk.7-12 The CFH Y402H single-nucleotide polymorphism (SNP) (rs1061170) increases risk 1.4- to 1.5-fold for early AMD11 and 2.5- to 6.0-fold for late AMD.7
Vitamin D has anti-inflammatory and immune-modulating properties13 and is hypothesized to protect against the development of AMD.14 Animal models15-18 and epidemiologic studies19-21 of autoimmune disease support this hypothesis. In vivo research indicates that both the proteins for the vitamin D receptor (VDR) and the enzyme 1-α-hydroxylase, which converts the major circulating metabolite of vitamin D (25-hydroxyvitamin D [25(OH)D]) to its active hormone calcitriol (1,25-dihydroxyvitamin D), are expressed in the retina.22
Previous studies have found that decreased odds of AMD are associated with high compared with low concentrations of 25(OH)D,14,23,24 vitamin D intake from foods,23,25 and certain polymorphisms in genes involved in vitamin D metabolism,26 although other studies27-29 do not support an association. Research in the Carotenoids in Age-Related Eye Disease Study (CAREDS) revealed that postmenopausal women younger than 75 years had an increased odds of AMD if they had low vs high vitamin D status assessed with intake of vitamin D and 25(OH)D concentrations.23 We proposed to investigate whether this previously observed association between 25(OH)D and AMD was stronger in women with established AMD risk genotypes, including several that influence inflammatory pathways, and to investigate the association between AMD and SNPs in genes involved in vitamin D transport, metabolism, and genomic function.
Deficient vitamin D status has been associated with increased odds of age-related macular degeneration (AMD); modification by genetic risk for AMD is unknown.
Women deficient in vitamin D, with 2 high-risk alleles (CFH Y202H or CFI [rs100333900]), were at increased odds of having AMD.
Study limitations include small number of cases in joint effect cells and possible spurious findings from multiple testing.
The possibility of residual confounding exists, and the use of prevalent AMD cases limits our ability to determine causality.
Maintenance of adequate vitamin D status, especially in persons at high genetic risk, should be considered for AMD prevention.
CAREDS was conducted to study the association of lutein and zeaxanthin with AMD.30-32 A total of 2005 women enrolled in CAREDS from May 14, 2001, through January 31, 2004, a mean of 6 years after the Women’s Health Initiative Observational Study (WHI-OS) baseline (October 1, 1993, to December 31, 1998). This research study was approved at all institutions by their institutional review boards, and the study procedures conformed to the Declaration of Helsinki. Written informed consent was obtained from all participants.
All CAREDS participants were administered questionnaires at WHI-OS and CAREDS baseline to assess demographic characteristics, family and medical history, and lifestyle habits inclusive of relevant AMD risk factors. Gradable retinal photographs were obtained from 1853 of 1894 women attending CAREDS’ baseline study visits (May 14, 2001, through January 31, 2004). Four additional women were included who had no retinal photographs but provided a physician’s confirmation of AMD status. Of these, 1230 had sufficient serum amounts at WHI-OS baseline (October 1, 1993, to December 31, 1998) for 25(OH)D assessment, gave approval for use of their genetic data, had sufficient DNA for genotyping, and passed quality assurance and control tests for genotyping.
Women enrolled in CAREDS but excluded because of missing serum 25(OH)D and genetic data (n = 775) had a similar prevalence of AMD and a similar mean intake of vitamin D compared with women with these data (n = 1230) (eTable 1 in the Supplement). Women with compared with women without missing data were slightly older (P = .01) and had healthier lifestyle scores (P = .06).
The current analyses are limited to the sample of women aged 54 to younger than 75 years (N = 913), in whom we previously observed an association between vitamin D status and AMD.23 We do not present data in women 75 years or older because of the small sample size (n = 317) and potential selective mortality bias in this older sample.23 A slightly larger sample (n = 1230) of women younger than 75 years was available for the analysis of the association between AMD and SNPs of vitamin D–related genes because women were not further excluded for missing 25(OH)D data.
Stereoscopic retinal fundus photographs were taken at CAREDS baseline (May 14, 2001, through January 31, 2004) and graded by the University of Wisconsin Fundus Photography Reading Center using the Age-Related Eye Disease Study (AREDS) protocol.33 The outcome for these analyses was presence of early or late AMD (any AMD). Early AMD was classified similarly to AREDS category 3,33 including the presence of one or more large drusen (≥125 μm) or extensive intermediate drusen (≥360 μm when soft indistinct drusen were present or ≥650 μm when soft indistinct drusen were absent). Different from the AREDS category 3, the presence of early AMD also included having pigmentary abnormalities or an increase or decrease in pigmentation if accompanied by at least one drusen 63 μm or larger. Late AMD included geographic atrophy (noncentral or central), neovascularization, or exudation in the center subfield. eTable 2 in the Supplement lists the distribution of AMD cases by severity. Most of these cases (133 of 142 [93.7%]) were early AMD. The reference group included women who had neither early nor late AMD, generally corresponding to AREDS categories 1 and 2.33
Fasting blood samples collected at WHI-OS baseline (October 1, 1993, to December 31, 1998) were assessed for serum concentrations of 25(OH)D using the Diasorin LIAISON chemiluminescence method (Heartland Assays Inc).23 We adjusted for season of blood draw by regressing 25(OH)D concentrations on month of blood draw using a nonparametric regression technique.23,34 Residuals were added to the sample 25(OH)D mean to obtain season-adjusted 25(OH)D concentrations, which are presented in the following analyses.
Serum, obtained at WHI-OS baseline, was stored and frozen at −80°C until DNA was extracted from the buffy coats and genotyped. Within CAREDS, a custom 768-SNP panel was designed to genotype candidate genes for carotenoid status,35 vitamin D status,36 and risk of AMD. The panel included 5 established genetic variants for late AMD: Y402H (rs1061170) in CFH,7 rs10033900 in CFI,12 rs641153 in CFB/C2,8,9 rs2230199 in C3,10 and A69S (rs10490924) in ARMS2.8,37 The SNPs from 6 vitamin D–related genes, some of which have been previously described in CAREDS,36 were also included: DHCR7, CYP2R1, CYP27B1, CYP24A1, VDR, and GC (see footnotes in Table 2 and eTable 3 for database links to individual variants).
Genotyping was conducted at Case Western Reserve University. Genotyping of all noted SNPs above, but not CFH Y402H, were conducted with an Illumina Custom GoldenGate Assay, and genotype calls were made using Illumina Genome Studio (Illumina Inc). Genotyping of Y402H was conducted using the KASP Assay at LCG Genomics and called via the KASP SNP Genotyping System. CFH Y402H genotypes were imputed using MACH (http://csg.sph.umich.edu//abecasis/MACH/index.html) when there was insufficient DNA for KASP genotyping after Illumina genotyping (approximately 3%). Imputation was performed using the available chromosome 1 SNPs from Illumina (n = 14 SNPs) and 1000 Genomes Project European ancestry panel as a reference. The resulting R2 from imputing Y402H was 99.5%. All SNPs passed standard quality control filters,38 including Hardy-Weinberg equilibrium χ2P > 1.0 × 10−6, minor allele frequency greater than 0.01, and genotype call rates greater than 95%.
We created 4 categories of vitamin D status based on 25(OH)D and the Institute of Medicine’s Dietary Reference Intakes39 (<12 [deficient], ≥12 to <20 [inadequate], ≥20 to <30 [adequate], and ≥30 [adequate] ng/mL [to convert to nanomoles per liter, multiply by 2.496]). We categorized women into 3 genotype groups for each SNP according to whether they had 1 or 2 high-risk alleles or were a noncarrier for each risk gene (additive genetic model). For CFB/C2, we combined women with 1 and 2 copies of the minor allele (A) owing to low number of homozygous women (nAA = 10) (dominant genetic model with respect to the minor allele).
Logistic regression was used to estimate age-adjusted odds ratios (ORs) and 95% CIs for AMD by (1) vitamin D status, (2) established AMD risk genotype, and (3) combined categories of vitamin D and risk genotype. For the joint analyses, the reference group was the hypothesized lowest-risk group, defined as women with a 25(OH)D concentration of 30 ng/mL or greater and a genotype indicative of low AMD risk. The ORs in the joint analysis were adjusted for the following covariates used in the previous vitamin D status and AMD analysis: smoking pack-years, iris pigmentation, self-reported cardiovascular disease, self-reported diabetes status, and hormone use status.23 A P for ordinal trend across vitamin D status categories was determined within each genotype class.
To test for deviation from a multiplicative interaction, we examined the P value for the interaction term (25[OH]D*genotype) using genotype (0, 1, or 2 risk alleles) and vitamin D status categories as ordinal variables. An interaction term with P < .05 was considered statistically significant. A deviation from an additive effect was examined using the synergy index (SI).40 An SI greater or less than 1.0 indicated that genotype and vitamin D status act jointly more than or less than additively, respectively.
To address our second study aim, logistic regression was used to estimate the age-adjusted ORs and 95% CIs for AMD by variants in vitamin D–related genes using an additive genetic model.
All analyses were conducted using SAS statistical software, version 9.2 (SAS Institute Inc).
Among the 913 women, 550 had adequate levels of vitamin D (≥20 ng/mL), 275 had inadequate levels (≥12 to <20 mg/mL), and 88 had deficient levels (<12 ng/mL). Women with deficient compared with adequate vitamin D status were less likely to be white, were less likely to have high incomes, were less likely to have an educational level beyond high school, were more likely to be nondrinkers, were less likely to have healthy diet patterns or engage in physical activity, were more likely to have lower self-reported ocular visible sun exposure, were more likely to be obese, and were less likely to use hormone replacement therapy (Table 1).
Age-adjusted odds of AMD are reported by vitamin D status and genotypes of high-risk AMD genes and vitamin D–related genes. Women with deficient (<12 ng/mL) compared with adequate (≥30 ng/mL) status had a 2.6-fold increased odds of AMD (95% CI, 1.3-5.2), those with inadequate status (≥12 to <20 ng/mL) had a 1.5-fold increase (95% CI, 0.8-2.6), and those with adequate status (≥20 to <30 ng/mL) had a 1.6-fold increase (95% CI, 0.9-2.7) (P for trend = .01). There was a more than 2-fold increased odds of AMD among women with 2 risk alleles for CFH (CC) or ARMS2 (AA) compared with noncarriers (Table 2). The P for trend = .04 for increasing number of risk alleles for CFI. The SNPs in CYP2R1 (rs11819875 and rs12418214) and VDR (rs11168275, rs2189480, and rs2239186) were associated with increased odds of AMD (eTable 2 in the Supplement).
Table 3 details the joint effects of genotypes by vitamin D status. The adjusted ORs presented in these tables differ minimally from the ORs adjusted only for age. There was 6.7-fold (95% CI, 1.6-28.2) increased odds of AMD among vitamin D–deficient women with 2 risk CFH alleles (CC) compared with noncarriers with adequate vitamin D status (≥30 ng/mL), with an SI of 1.4 (95% CI, 1.1-1.7). There was 6.3-fold (95% CI, 1.6-24.2) increased odds of AMD among vitamin D–deficient women with 2 risk CFI alleles (AA) relative to noncarriers with adequate vitamin D status, with an SI of 1.4 (95% CI, 1.1-1.7; P for interaction = .02). Further adjustment of models for educational level, principal components from principal component analysis using 176 ancestry informative markers, body mass index (BMI) (calculated as the weight in kilograms divided by height in meters squared), and recreational physical activity minimally influenced results. There was no evidence of an interaction between vitamin D status and the ARMS2, CFB/C2, and C3 genotypes.
Table 3 also presents the P for trend values for the odds of AMD across ordinal decreasing concentrations of 25(OH)D stratified by genotype. There was a P for trend < .05 for women with 2 high-risk CFH alleles (CC), 2 high-risk CFI alleles (AA), and noncarriers of the ARMS2 high-risk allele.
This study examined the joint effects of vitamin D status and high-risk genotypes on AMD. We observed a multiplicative interaction between vitamin D status and CFI, suggesting that the relative odds of AMD among women with deficient vs adequate vitamin D status differed by CFI genotype. We also observed additive interactions between vitamin D status and both CFH and CFI genotype. These additive interactions suggest that the greatest burden (attributable risk) of AMD may be in vitamin D–deficient women with 2 high-risk alleles (CFH or CFI), indicating that the burden is above that expected from the addition of these 2 exposures alone.41 Although the relative odds of AMD by vitamin D status may be similar in different CFH genotypes, the higher incidence of AMD among women with 2 high-risk CFH alleles (CC) (compared with one or none) may to lead to a greater burden (excess fraction) of AMD cases in vitamin D–deficient vs adequate women than in other CFH genotypes.41,42 Additive interaction might also be considered evidence of biological synergy.
We hypothesize that vitamin D suppresses a proinflammatory state in the retina via its genomic functions.43 Calcitriol is thought to modulate the adaptive immune response to suppress damaging inflammation44 by decreasing immune cell proinflammatory cytokine production,45-48 inhibiting dendritic cell maturation,49 inhibiting T- and B-lymphocyte proliferation,45,50,51 and inducing T-regulatory cell function.52 Polymorphisms in proteins essential to the complement cascade increase the risk of AMD.7-12 The CFH Y402H polymorphism53,54 results in a CFH protein with decreased C-reactive protein binding at this site.54,55 Both C-reactive protein and the CFH protein form a protein complex involved in inhibition of the complement cascade, which works less efficiently for those homozygous for the CFH Y402H risk allele.54,56 The CFI acts to inhibit the complement cascade by inactivating C3b and C4b,12,57 but this regulation requires the cofactor of CFH,12,57 illustrating the interconnectedness of these 2 proteins in cascade inhibition. Our study’s results suggest that being vitamin D deficient might impair one’s ability to suppress a localized inflammatory response, which when coupled with a dysfunctional complement pathway response could lead to increased risk of AMD above that expected from either independent risk factor alone. A study in aged mice58 found that vitamin D administration led to reductions in complement component C3b retinal expression (Bruch membrane) compared with controls. Currently, a biologic mechanism for a synergistic interaction between vitamin D status and complement pathway protein function is unknown.
Some14,25,26 but not all28,29 epidemiologic studies support a role of vitamin D in AMD. In addition to vitamin D intake or 25(OH)D, vitamin D status can also be inferred from genotypes previously associated with serum 25(OH)D. This is an underlying tenet of the method known as mendelian randomization, which is an increasingly used method in epidemiology to test unconfounded, causal associations between exposures and disease.59 Morrison et al26 observed that variants (rs1570669, rs1570670, rs2274130, rs2296239, rs4809957) in the vitamin 1,25(OH)2D catabolizing CYP24A1 gene were associated with a decreased odds of AMD. We examined these SNPs and also an SNP from a genome-wide association meta-analysis (rs6013897)60 and another that is a nonsynonymous (coding) SNP (rs35031736) in an effort to more broadly capture variation in this gene. We observed that 2 polymorphisms in the CYP2R1 gene and 3 in the VDR gene were associated with increased odds of AMD. However, these SNPS were not found to be predictors of 25(OH)D status in 2 large genome-wide association studies60,61 or SNPs known to influence the function of the VDR.62 Adjustment for multiple testing63 would have resulted in no statistically significant findings. Discrepancies in study findings may be explained by differences in stages of AMD between study samples because there was a large proportion of late AMD cases (36%-38%) in the previous study26 compared with CAREDS (6%; n = 4 neovascular, n = 5 geographic atrophy).
Few studies64-69 have examined associations between dietary factors and genes on AMD risk (K.J.M., unpublished data, 2014) and none with 25(OH)D. Previous literature has observed that intake of fish (a rich food source of vitamin D)69 and ω3 docosahexaenoic fatty acids (a nutrient concentrated in fish)68 were protective against progression to late AMD in those with high genetic risk. Vitamin D status may partly explain these findings.
It is also possible that vitamin D status is a marker of overall healthy lifestyle, and findings with respect to 25(OH)D are confounded by such factors as diet, body fatness, and physical activity, factors correlated with vitamin D status.23 A previous study70 found the greatest odds for late AMD in persons with the high-risk CFH Y402H genotype and high BMI. Results in CAREDS revealed that a healthy lifestyle score was associated with a reduced odds of AMD71 and that the greatest odds of disease was in women with the CC CFH Y402H genotype and low healthy lifestyle score (K.J.M., unpublished data, 2014). The findings of these studies parallel our findings with vitamin D status. We adjusted ORs for BMI and physical activity, but this did not influence our study conclusions. Difficulty in adjusting for highly correlated variables makes it impossible outside the context of a clinical trial to know whether vitamin D status causally influences risk for AMD.
This study was limited by a small sample size for the investigation of interactions, with small numbers of cases within joint effect cells leading to wide CIs. It is possible our findings are purely by chance because we did not adjust for multiple testing. The possibility of residual confounding cannot be excluded because this was an observational study. Although this study assessed prevalent AMD, ocular photographs were taken approximately 6 years after assessment of vitamin D status. Only 1.9% (23 of 1230) of CAREDS women with 25(OH)D data, genetic data, and fundus photographs self-reported having AMD at WHI-OS baseline (October 1, 1993, to December 31, 1998). Early AMD is asymptomatic, so it is unlikely that behavior changes as a result of AMD occurred before the WHI-OS baseline blood assessment, resulting in reverse causality. Because our study included primarily highly educated white women, our findings may not be generalizable to other populations.
Despite these limitations, minimal data exist on interactions between dietary and genetic factors in the context of age-related eye disease. To the best of our knowledge, effect modification of genetic risk by vitamin D status has not previously been explored. This cohort of postmenopausal women is very well defined, with detailed data on AMD risk factors and graded retinal photographs for age-related eye disease, and adds to the existing body of literature. Our study provides evidence of a suggestive joint effect between vitamin D status and genotypes of complement factor genes. Maintenance of an adequate vitamin D status and likely an overall healthy lifestyle may reduce the total burden of early AMD to the greatest extent in those with high genetic risk for genes in the complement cascade.
Submitted for Publication: March 12, 2015; final revision received June 12, 2015; accepted June 17, 2015.
Corresponding Author: Amy E. Millen, PhD, Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, 270 Farber Hall, Buffalo, NY 14214-8001 (email@example.com).
Published Online: August 27, 2015. doi:10.1001/jamaophthalmol.2015.2715.
Author Contributions: Dr Mares had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Millen, Meyers, Mares.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Millen.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Millen, Meyers, Liu, Engelman, Iyengar.
Obtained funding: Millen, Wallace, Iyengar, Mares.
Administrative, technical, or material support: Wallace, Iyengar.
Study supervision: Millen, Meyers, Mares.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Millen reporting receiving support as a coinvestigator on a vitamin D–related grant funded by the Mushroom Council (grant 10008) during this work. No other disclosures were reported.
Funding/Support: Carotenoids in Age-Related Eye Disease Study is supported by grants EY013018 and EY016886 from the National Eye Institute of the National Institutes of Health, the Research to Prevent Blindness, and the Retina Research Foundation. The Women’s Health Initiative program is funded by contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C from the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Additional Contributions: Margaret M. DeAngelis, PhD, Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, assisted in selecting vitamin D–related genes and associated SNPs. We thank the WHI investigators and staff for their dedication and the study participants for making the program possible.
Additional Information: A listing of WHI investigators can be found at http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf.
Program Office, Clinical Coordinating Center, Investigators and Academic Centers for the Women’s Health Initiative. Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller (National Heart, Lung, and Blood Institute, Bethesda, Maryland); Clinical Coordinating Center: Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg (Fred Hutchinson Cancer Research Center, Seattle, Washington); Investigators and Academic Centers: JoAnn E. Manson (Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts), Barbara V. Howard (MedStar Health Research Institute/Howard University, Washington, DC), Marcia L. Stefanick (Stanford Prevention Research Center, Stanford, California), Rebecca Jackson (The Ohio State University, Columbus), Cynthia A. Thomson (University of Arizona, Tucson/Phoenix), Jean Wactawski-Wende (University at Buffalo, Buffalo, New York), Marian Limacher (University of Florida, Gainesville/Jacksonville), Robert Wallace (University of Iowa, Iowa City/Davenport), Lewis Kuller (University of Pittsburgh, Pittsburgh, Pennsylvania), Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, North Carolina); Women’s Health Initiative Memory Study: Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, North Carolina).
Create a personal account or sign in to: